Investor Moves
| Name | Value | Action | Change | Price | Current Price |
|---|---|---|---|---|---|
Ken GriffinCitadel Advisors $-30.3K ExitQ1 2026 $30k -- $0.543 | |||||
News
accessnewswire.comProtagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partneraccessnewswire.comMay 19
accessnewswire.comProtagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114accessnewswire.comApr 23
defenseworld.netContrasting Vanda Pharmaceuticals (NASDAQ:VNDA) and Atrinsic (NASDAQ:PTIX)defenseworld.netApr 14